TABLE 2.
Univariate Analysis of Factors Associated With Increased LOS in Children With Eczema Herpeticum
| Variable | Unadjusted β Coefficient (95% CI) | P |
|---|---|---|
| Demographics | ||
| Age, y | −0.01 (−0.02 to 0.01) | .35 |
| Gender | ||
| Male | Reference | — |
| Female | 0.01 (−0.06 to 0.08) | .79 |
| Race/ethnicity | ||
| Non-Hispanic white | Reference | — |
| Non-Hispanic black | 0.14 (0.05 to 0.22) | .002 |
| Hispanic | 0.16 (−0.16 to 0.33) | .06 |
| Other | 0.17 (0.04 to 0.31) | .012 |
| APR-DRG severity classification | ||
| Minor | Reference | — |
| Moderate | 0.41 (0.10 to 0.73) | .012 |
| Major | 1.81 (0.28 to 3.34) | .022 |
| Extreme | 2.39 (1.27 to 3.50) | <.001 |
| ICU admission | 0.43 (−0.03 to 0.88) | .065 |
| Therapy and laboratory testing | ||
| Acyclovir day of initiation | ||
| 1 | Reference | — |
| 2 | 0.17 (0.07 to 0.27) | .001 |
| 3 | 0.53 (0.34 to 0.72) | <.001 |
| 4–7 | 0.85 (0.62 to 1.08) | <.001 |
| Antibiotics (oral or intravenous) | 0.58 (0.48 to 0.67) | <.001 |
| Topical antibiotics | 0.30 (0.23 to 0.37) | <.001 |
| Systemic corticosteroids | 0.36 (0.16 to 0.55) | .001 |
| Topical corticosteroids | 0.19 (0.11 to 0.27) | <.001 |
| Topical calcineurin inhibitors | 0.16 (−0.02 to 0.33) | .08 |
| Blood culture | 0.36 (0.27 to 0.45) | <.001 |
| Herpes simplex virus testing | 0.24 (0.10 to 0.37) | .001 |
| Concurrent infections | ||
| Bloodstream infection | 0.98 (0.71 to 1.25) | <.001 |
| S aureus infection | 0.39 (0.33 to 0.45) | <.001 |
APR-DRG indicates all patient refined-diagnosis related groups.